advertisement
 

  Back to Ask the Diabetes Team Ask the Diabetes Team
Question:

From Illinois, USA:

I have a four year old daughter who was diagnosed with type 1. I was wondering if you have heard of any research done on the GAD protein and how it relates to finding a cure. I received an article that this protein is thought to be linked to the beginnings of a cure.

Would it be helpful to have my other 2 non-diabetic children tested for the antibodies? As far as I know they did not test my daughter for the antibody. We are Caucasian so maybe that is why.

Answer:

Earlier work in the NOD mouse model had shown that injections of GAD could produce a protective, so called Th2 type of lymphocyte response, to diabetes following injections of GAD. A Swedish firm called DIAMYD has now produced an isoform of GAD called GAD65 and have completed a small Phase 1 study in man as a test of safety. There were no ill effects and a larger Phase II study has begun, I think in Germany, to test safety more thoroughly. If all goes well again the proposal is to carry out a full clinical trial in late onset Type 1A Diabetes in adulthood.

You should consult with your doctor; but yes, it would make sense to carry out an antibody test on the two siblings even though the chance of either of them being positive is only around 5%.

DOB

DTQ-20000104140329
Original posting 8 Mar 2000
Posted to Research: Cure

  
advertisement


                 
  Home Return to Top

Last Updated: Tuesday April 06, 2010 15:09:10
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.